Justin J. Hasford

Partner

vCard

Justin J. Hasford

Partner

+1 202 408 4175 +1 202 408 4175
justin.hasford@finnegan.com justin.hasford@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Justin's work in

Justin Hasford has experience in all areas of intellectual property law. His practice focuses on complex patent litigation at the trial and appellate levels on behalf of pioneer pharmaceutical companies. He has particular experience with cases arising from Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act and in post-grant proceedings before the Patent Trial and Appeal Board (PTAB). Justin has also litigated trade secret, antitrust, and business method patent cases.

Recognized as a Global Leader for three consecutive years (2023-2025) by Intellectual Asset Management’s (IAM) Strategy 300 and as a Next Generation Lawyer by The Legal 500 U.S. for patent litigation, Justin counsels clients on issues of infringement, validity, enforceability, trade secret, antitrust, unfair competition, licensing, due diligence, and IP portfolio management. He has extensive experience advising clients regarding the interplay between patent and regulatory laws, including Orange Book listing of patents for drugs approved by the Food and Drug Administration (FDA).

Justin regularly speaks on the protection of U.S. intellectual property rights. He has also successfully represented a variety of low-income clients on a pro bono basis.

NOTE: No aspect of these rankings has been approved by the Supreme Court of New Jersey. Further information on methodologies is available via these links.

Et Cetera

Co-recipient along with his wife, Sarah Hasford, of the American Chemical Society’s Howard and Sally Peters Award for non-traditional careers in chemistry, 2017.
Inducted into the Warren County (Kentucky) Public Schools Hall of Distinguished Alumni, 2017.
Selected by his peers as an American Chemical Society Fellow, 2015.
Received the Roger D. Middlekauf Award for outstanding service to the Division of Chemistry and the Law of the American Chemical Society, 2011.
Appointed in December 2008 to serve as deputy general secretary of the Second Beijing International Pharmaceutical and Chemical Intellectual Property Forum in August 2009.

Experience

In re Lumify

Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients.

3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock

Mitsubishi Tanabe Pharma Corporation v. Shanghai Auzone Biological Technology Co., Ltd et al.

Representing Mitsubishi Tanabe Pharma in litigation matters related to Radicava ORS (edaravone) used to treat patients with amyotrophic lateral sclerosis (ALS).

2:25-cv-03326, D.N.J., Judge Cecchi
1:23-cv-00759, D. Del., Judges Burke, Connolly, Hall
1:24-cv-01423, D. Del., Judge Hall
1:24-cv-00549, D. Del., Judge Hall

Arvinas Operations, Inc. et al. v. Qian et al.

Defending Accutar Biotechnology, Inc. in a trade secret lawsuit brought by Arvinas regarding alleged trade secrets concerning breast cancer therapies.

3:22-cv-00717, D. Conn., Judges Chatigny, Richardson

Represents Castle Retail in patent litigation brought by Hawk Technology Systems in district court and on appeal. The district court ruled in Castle Retail’s favor, granting Castle Retail’s Rule 12 motion and invalidating Hawk’s patent claims related to video surveillance technology. On appeal the Federal Circuit affirmed the district court ruling. The district court then granted our client more than $106k in attorneys fees, finding the entirety of Finnegan’s attorneys fees to be reasonable.

2:20-cv-02766, W.D. Tenn., Judge McCalla
22-1222, Fed. Cir., Judges Cunningham, Hughes, Reyna

Represented Eli Lilly in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Eli Lilly's Cymbalta®. The S.D. Indiana entered judgment before trial in favor of Eli Lilly and against all the ANDA filers on all issues, resulting in orders and judgment maintaining Cymbalta's® market exclusivity through the end of its patent life.

1:08-cv-01547, S.D. Ind., Judges Baker, Lawrence, Pratt

Finnegan represented Bausch Health Companies (f/k/a Valeant), Salix and Progenics—the innovators and patent owner—in this Hatch-Waxman infringement action in the District of New Jersey. A bench trial was held, and the presiding judge issued an 83-page opinion upholding the validity of the asserted patent claims and finding those claims infringed, thereby entering judgment in favor of the plaintiffs through the life of the patents covering Relistor® tablets, extending through 2030.

2:16-cv-09038, D.N.J., Judges Chesler, Waldor

Insights

Webinar

Recent Pharmaceutical, Chemical, and Biotech Case Law on Infringement Under the Doctrine of Equivalents Recent Pharmaceutical, Chemical, and Biotech Case Law on Infringement Under the Doctrine of Equivalents

March 12, 2026

Webinar

What’s Working at the PTAB Now: Strategies for Petitioners and Patent Owners What’s Working at the PTAB Now: Strategies for Petitioners and Patent Owners

March 4, 2026

Webinar

Protect Your Innovations: Recent Patent Case Law in the Life Sciences Protect Your Innovations: Recent Patent Case Law in the Life Sciences

February 11, 2026

Webinar

Recent Pharmaceutical, Chemical, and Biotech Case Law on Infringement Under the Doctrine of Equivalents

February 18, 2025

Webinar

Recent Court Decisions in the Life Sciences Recent Court Decisions in the Life Sciences

May 22, 2024

Webinar

At the PTAB Blog

Petitioners Fail on Inherency but Prevail on Obviousness Petitioners Fail on Inherency but Prevail on Obviousness

February 9, 2024

News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Intellectual Asset Management (IAM)

Award/Ranking

Seven Finnegan Partners Named to IAM Strategy 300 Global Leaders 2026

November 19, 2025

Intellectual Asset Management (IAM)

Press Release

Federal Circuit Affirms Victory for Finnegan Client Castle Retail Against Hawk Technology Systems Federal Circuit Affirms Victory for Finnegan Client Castle Retail Against Hawk Technology Systems

November 17, 2025

Commentary

Fed. Circ. Clears Fees for Grocer After It Beat Camera IP Suit Fed. Circ. Clears Fees for Grocer After It Beat Camera IP Suit

November 14, 2025

Law360

Media Mention

Grocery Chain’s Fee Award Affirmed After Patent Dispute Victory Grocery Chain’s Fee Award Affirmed After Patent Dispute Victory

November 14, 2025

Bloomberg Law

Award/Ranking

Seven Finnegan Attorneys Named to the 2025 IAM Strategy 300 List Seven Finnegan Attorneys Named to the 2025 IAM Strategy 300 List

August 13, 2025

Intellectual Asset Management (IAM)

American Chemical Society, Chemistry and the Law Division
(immediate past chair, 2009; chair-elect, 2007; chair, 2008; alternate councilor, 2016-present; archivist, 2016-present; co-secretary, 2011-2015; program chair, 2009-2010; program chair, 2005-2007)
American Bar Association
American Intellectual Property Law Association
District of Columbia Bar
Virginia Bar Association

Admissions and Education

Admissions

U.S. Patent and Trademark Office
New Jersey
District of Columbia
Virginia

U.S. District Court, W.D. Texas
U.S. District Court, District of Columbia
U.S. District Court, D. New Jersey
U.S. Court of Appeals, D.C. Circuit
Supreme Court of the United States
U.S. District Court, W.D. Virginia
U.S. Court of Appeals, Federal Circuit
U.S. District Court, E.D. Virginia
U.S. District Court, W.D. Tennessee

Education

University of Virginia School of Law: J.D., 2003

Vanderbilt University: B.S., Chemistry, with high honors, and Molecular Biology, magna cum laude, 1998

Justin's Practices

Global IP Enforcement, Litigation, and Trials: Branded Hatch-Waxman (ANDA) Litigation and Trials; Patent Litigation and Trials
Patent Office Invalidation Proceedings: Ex Parte Reexamination (EPR); PTAB Invalidation Proceedings: IPR and PGR
Prosecution and Portfolio Management: Due Diligence; Ex Parte Reexamination (EPR); Opinions and Counseling

Justin's Industries

Chemicals, Industrials, and Materials: Chemical
Life Sciences: Biotechnology; Digital Health; Pharmaceutical

Justin J. Hasford

Et Cetera

Experience

Insights

News

Professional Activities

Admissions

Education

Justin's Practices

Justin's Industries